Michael A. Postow

65.1k total citations · 6 hit papers
231 papers, 15.4k citations indexed

About

Michael A. Postow is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Michael A. Postow has authored 231 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Oncology, 70 papers in Immunology and 68 papers in Molecular Biology. Recurrent topics in Michael A. Postow's work include Cancer Immunotherapy and Biomarkers (163 papers), CAR-T cell therapy research (98 papers) and Melanoma and MAPK Pathways (53 papers). Michael A. Postow is often cited by papers focused on Cancer Immunotherapy and Biomarkers (163 papers), CAR-T cell therapy research (98 papers) and Melanoma and MAPK Pathways (53 papers). Michael A. Postow collaborates with scholars based in United States, France and Italy. Michael A. Postow's co-authors include Matthew D. Hellmann, Robert Sidlow, Jedd D. Wolchok, Margaret K. Callahan, Claire F. Friedman, Tracy Proverbs‐Singh, Mario E. Lacouture, Katherine S. Panageas, Richard D. Carvajal and Katja Schindler and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Michael A. Postow

219 papers receiving 15.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

2018 3.2k citations Michael A. Postow, Matthew D. Hellmann et al. profile →
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

2015 1.2k citations Michael A. Postow, Jedd D. Wolchok et al. profile →
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

2015 808 citations Parisa Momtaz, Michael A. Postow et al. Journal of Clinical Oncology profile →
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

2016 631 citations Michael A. Postow et al. profile →
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

2018 408 citations Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine profile →
Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

2015 306 citations Jedd D. Wolchok, Christopher A. Barker et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael A. Postow	12.2k	5.2k	3.1k	2.9k	1.3k	231	15.4k
Ryan J. Sullivan	9.5k 0.8×	3.3k 0.6×	2.3k 0.7×	4.0k 1.4×	1.1k 0.8×	395	13.4k
Douglas B. Johnson	9.8k 0.8×	4.0k 0.8×	2.4k 0.8×	4.6k 1.6×	970 0.8×	293	14.1k
Patrick A. Ott	11.3k 0.9×	5.6k 1.1×	3.5k 1.1×	3.6k 1.3×	1.6k 1.2×	240	15.6k
Svetomir N. Markovic	6.9k 0.6×	4.0k 0.8×	1.5k 0.5×	3.4k 1.2×	988 0.8×	349	12.2k
Christian U. Blank	10.6k 0.9×	6.6k 1.3×	2.0k 0.6×	5.0k 1.7×	795 0.6×	272	14.7k
Vanna Chiarion‐Sileni	7.3k 0.6×	3.1k 0.6×	2.2k 0.7×	4.1k 1.4×	548 0.4×	244	10.4k
Gilbert Deray	9.8k 0.8×	4.3k 0.8×	4.0k 1.3×	2.2k 0.8×	853 0.7×	115	13.3k
Jason J. Luke	8.2k 0.7×	4.9k 0.9×	2.1k 0.7×	4.7k 1.6×	799 0.6×	296	13.2k
Steven O’Day	9.5k 0.8×	4.6k 0.9×	2.4k 0.8×	4.7k 1.7×	662 0.5×	198	12.9k
Rimda Wanchoo	9.9k 0.8×	4.3k 0.8×	4.0k 1.3×	2.1k 0.7×	666 0.5×	51	12.7k

Countries citing papers authored by Michael A. Postow

Since Specialization

Citations

This map shows the geographic impact of Michael A. Postow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Postow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Postow more than expected).

Fields of papers citing papers by Michael A. Postow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Postow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Postow. The network helps show where Michael A. Postow may publish in the future.

Co-authorship network of co-authors of Michael A. Postow

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Postow. A scholar is included among the top collaborators of Michael A. Postow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Postow. Michael A. Postow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marks, Kathryne E., Alice Horisberger, Nilasha Ghosh, et al.. (2025). Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma. JCI Insight. 11(2).

Mao, Jun J., Erin F. Gillespie, Angela Green, et al.. (2025). Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment. npj Digital Medicine. 8(1). 29–29. 2 indexed citations

Smithy, James W., et al.. (2025). Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis. Nature Communications. 16(1). 6619–6619. 1 indexed citations

Postow, Michael A., Gabriela Burgos, Flavia Ejzykowicz, et al.. (2024). First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.. Journal of Clinical Oncology. 42(16_suppl). 9539–9539. 1 indexed citations

Smithy, James W., Ronak Shah, Matthew Adamow, et al.. (2024). Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clinical Cancer Research. 30(16). 3407–3415. 4 indexed citations

Valle, Diane M. Del, Graham J. Britton, Alice Chen-Liaw, et al.. (2024). Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. The Journal of Experimental Medicine. 222(1). 5 indexed citations

Hong, David S., Michael A. Postow, Bartosz Chmielowski, et al.. (2023). Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research. 29(12). 2210–2219. 48 indexed citations

Smithy, James W., Colleen Maher, Alexander N. Shoushtari, et al.. (2023). Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).. Journal of Clinical Oncology. 41(16_suppl). 9517–9517.

Chapman, Paul B., Mark Klang, Michael A. Postow, et al.. (2023). Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib. Cancer Research Communications. 3(12). 2447–2454. 4 indexed citations

10.

Badran, Yousef R., Fangwen Zou, Sienna Durbin, et al.. (2023). Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. 11(6). e007195–e007195. 17 indexed citations

11.

Adamow, Matthew, Colleen Maher, Michael A. Postow, et al.. (2023). A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy. Cell Reports Methods. 3(8). 100546–100546. 3 indexed citations

12.

Ascierto, Paolo A., Lisa H. Butterfield, Olivera J. Finn, et al.. (2022). The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021. Journal of Translational Medicine. 20(1). 179–179. 2 indexed citations

13.

Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884. 39 indexed citations

14.

Bartlett, Edmund K., Jessica Flynn, Katherine S. Panageas, et al.. (2019). High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy. Cancer. 126(1). 76–85. 104 indexed citations

15.

Rodig, Scott J., Daniel Gusenleitner, Donald Jackson, et al.. (2018). MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine. 10(450). 408 indexed citations breakdown →

16.

Khalil, Danny N., Michael A. Postow, Nageatte Ibrahim, et al.. (2016). An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research. 22(21). 5204–5210. 19 indexed citations

17.

Martens, Alexander, Kilian Wistuba‐Hamprecht, Jianda Yuan, et al.. (2016). Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research. 22(19). 4848–4858. 141 indexed citations

18.

Weber, Jeffrey S., Laura A. Levit, Peter C. Adamson, et al.. (2014). American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology. 33(3). 278–284. 81 indexed citations

19.

Kitano, Shigehisa, Michael A. Postow, Carly G.K. Ziegler, et al.. (2014). Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. Cancer Immunology Research. 2(8). 812–821. 111 indexed citations

20.

Barker, Christopher A., Michael A. Postow, Shaheer Khan, et al.. (2013). Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma. Cancer Immunology Research. 1(2). 92–98. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact